Gilead Sciences gets EMA panel postive opinion recommending full marketing nod of Hepcludex for HDV Ruchika Sharma5 May 2023 1:30 PM ISTFoster City: Gilead Sciences, Inc. has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
Gilead Sciences, US square off in billion-dollar HIV drug patent trial Ruchika Sharma2 May 2023 3:46 PM ISTThe USFDA approved Gilead's Truvada for HIV prevention in 2012 and approved its related drug Descovy for the same purpose in 2019.
Gilead Sciences exercises option to license Nurix's investigational targeted protein degrader molecule NX-0479 Ruchika Sharma21 March 2023 5:22 PM ISTFoster City: Gilead Sciences, Inc. and Nurix Therapeutics, Inc., a clinical-stage biopharmaceutical company developing targeted protein...
Gilead Sciences secures USFDA okay for Trodelvy for pre-treated HR+/HER2- Metastatic Breast Cancer Ruchika Sharma4 Feb 2023 11:37 AM ISTTrodelvy (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate.
EMA validates marketing authorization application for Trodelvy for Pre-treated HR+/HER2- Metastatic Breast Cancer: Gilead Sciences Ruchika Sharma5 Jan 2023 4:30 PM ISTTrodelvy (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate.
Gilead Sciences to acquire all remaining rights to potential first-in-class immunotherapy GS-1811 from Jounce Therapeutics Ruchika Sharma28 Dec 2022 12:30 PM ISTJounce will receive proceeds of $67 million for this transaction, and Gilead will be solely responsible for all further research, development, and...
Gilead Sciences bags USFDA nod for Sunlenca to treat HIV-1 infection Ruchika Sharma23 Dec 2022 4:09 PM ISTLenacapavir is a breakthrough innovation with the potential to be a preferred and versatile foundational long-acting agent due to its therapeutic...
Gilead Sciences Trodelvy under USFDA priority review for adult patients with pretreated metastatic breast cancer Ruchika Sharma14 Oct 2022 2:30 PM ISTTrodelvy (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate.
Shilpa Medicare gets USFDA nod for Tenofovir Alafenamide Tablets Ruchika Sharma19 Sept 2022 11:25 AM ISTNew Delhi: Shilpa Medicare has recently announced that the Company has received U.S Food and Drug Administration (USFDA) tentative approval for...
Gilead Sciences' Kite gets European Commission nod for CAR T-cell therapy Tecartus Ruchika Sharma8 Sept 2022 4:00 PM ISTSanta Monica, Calif.: Kite, a Gilead Company has announced that the European Commission (EC) has approved its CAR T-cell therapy Tecartus...
Gilead Sciences bags European Commission nod for HIV drug Sunlenca Ruchika Sharma23 Aug 2022 1:30 PM ISTSunlenca is indicated in the European Union for the treatment of adults with multi-drug resistant HIV infection in combination with other...
Gilead Sciences to acquire MiroBio for Rs 3225 crore Ruchika Sharma9 Aug 2022 11:00 AM ISTThe acquisition will provide Gilead with MiroBio's proprietary discovery platform and entire portfolio of immune inhibitory receptor agonists.
